2
Total investments
1
Early stage
1
Mid stage
0
Late stage
7y
Years active
Portfolio
2 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Aug 2019
Ultivue develops innovative reagent-based solutions that maximize the biological information available from cells and tissue samples. The company's technology is being used to elucidate biological pathways and to validate clinically-relevant biomarkers. Ultivue is based in Cambridge, MA.
Our culture provides an exceptional work environment fostering innovation and collaboration to make a difference collectively. Ultivue’s employees are bright, flexible, and driven to create meaningful impact through our work. We work at a fast pace, but support each other achieve the work/life balance that helps us thrive as a company. Our entrepreneurial culture relies on contributions and input from all. Our bench of experienced managers provides mentoring and support to ensure front line staff make the most of their unique talents and energy.
Open Positions
Ultivue provides unique opportunities for talented individuals to bring all of themselves--their passion, expertise and creativity--to bear on collectively solving problems that matter.
For the full list of open positions and to apply please visit our website https://www.ultivue.com/careers. When submitting job application, make sure to submit both a resume and a cover letter.
Board Member
Feb 2019
HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and anti-tumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both completing Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently in Phase 2 clinical development, modulates the anti-tumor innate immune response.
Experience · 6 entries
All (6)
Investments (2)
Founder (1)
Board (2)
2022
Co-Founder, Cru Bio
Aug 2022
CRU BIO is dedicated to developing innovative therapies to address kidney and related diseases.
2019
Board Member
Aug 2019
Ultivue develops innovative reagent-based solutions that maximize the biological information available from cells and tissue samples. The company's technology is being used to elucidate biological pathways and to validate clinically-relevant biomarkers. Ultivue is based in Cambridge, MA.
Our culture provides an exceptional work environment fostering innovation and collaboration to make a difference collectively. Ultivue’s employees are bright, flexible, and driven to create meaningful impact through our work. We work at a fast pace, but support each other achieve the work/life balance that helps us thrive as a company. Our entrepreneurial culture relies on contributions and input from all. Our bench of experienced managers provides mentoring and support to ensure front line staff make the most of their unique talents and energy.
Open Positions
Ultivue provides unique opportunities for talented individuals to bring all of themselves--their passion, expertise and creativity--to bear on collectively solving problems that matter.
For the full list of open positions and to apply please visit our website https://www.ultivue.com/careers. When submitting job application, make sure to submit both a resume and a cover letter.
Board Member
Feb 2019
HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and anti-tumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both completing Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently in Phase 2 clinical development, modulates the anti-tumor innate immune response.
2018
6
6 Dimensions Capital
Venture Partner
2018
Venture Partner
2018
6 Dimensions Capital is a leading global healthcare investment firm with offices in Boston, San Francisco, Hong Kong and Shanghai.
The firm focuses on the investments of healthcare startups or growth stage companies with operations in the U.S., Europe, China, Israel and other countries.
We help and enable entrepreneurs to create and grow innovative healthcare businesses for the benefits of patients worldwide.
Show all 6 entries ↓
